Christian Caglevic

5PUBLICATIONS
43CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 25, 2026
Improving Gallbladder Cancer Outcomes with Antibody-Based Therapies and Immunological Profiling: A Literature Review.

|Jun 03, 2026
Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study.

|Oct 28, 2022
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.

Gilberto de Castro, Iveta Kudaba, Yi-Long Wu

|Aug 22, 2022
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations.

Christian Caglevic, Christian Rolfo, Ignacio Gil-Bazo

|Oct 31, 2020
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells.

Iosune Baraibar, Marta Roman, María Rodríguez-Remírez

Pageof 1

Frequent Collaborators

2 joint publications

Dariusz M Kowalski

1 joint publications

Marta Roman

1 joint publications

Elisabeth Guruceaga

1 joint publications

María Collantes